Molecular Pharmacology Program

The Hedvig Hricak Lab

Research

Hedvig Hricak, MD, PhD
Hedvig Hricak, MD, PhD
Carroll and Milton Petrie Chair

Our laboratory is working on establishing phenotypic signatures of cancer using multimodality anatomic and molecular imaging. We also aim to integrate multimodality imaging with anatomic pathology, genomics, and other molecular signatures to gain further insight into comprehensive molecular and anatomic tumor profiling. The goal is to further advance understanding of in vivo tumor biology and tumor heterogeneity (both spacial and temporal). We plan to develop and validate tumor biomarkers that can be used for treatment selection, assessment of treatment response or early detection of treatment resistance. Using advanced computational methods of radiomics and radiogenomics, we are evaluating how multimodality/multiplexing technology can advance our knowledge of tumor phenotypes and their associations with genomic mutations. We are also exploring targeted imaging and targeted therapies to ultimately expand the field of theranostics, which we believe is one of the future paths to precision medicine.

View Lab Overview

The Hedvig Hricak Lab

Publications Highlights

View All Publications

People

Hedvig Hricak, MD, PhD

Hedvig Hricak, MD, PhD

Carroll and Milton Petrie Chair

  • Radiologist Hedvig Hricak researches methodologies of molecular imaging of prostate and gynecologic tumors.
  • MD, University of Zagreb School of Medicine (Yugoslavia)
  • Dr. Med. Sc. Karolinska Institute (Sweden)
212-639-7284
Office Phone
View physician profile
Physician profile

Members

Vladimir Ponomarev
Vladimir Ponomarev

Associate Attending in the Radiochemistry and Imaging Sciences Service of the Department of Radiology

Amita Dave
Amita Dave

Director, Quantitative Imaging; and Deputy Service Chief Predictive Informatics in the Department of Medical Physics

Oguz Akin

Attending Radiologist, Director of Body MRI, Department of Radiology

Ida Haeggstroem
Ida Haeggstroem
Yousef Mazaheri

Attending in the Department of Medical Physics

Sungmin Woo

Assistant Attending Radiologist, Body Imaging Service, Department of Radiology

Lab Alumni
Jose Lobo

Senior Research Technician

Sarah M. Cheal

Research Fellow, R25T Molecular Imaging: Training for Oncology Program

Jason T. Lee

Research Fellow, R25T Molecular Imaging: Training for Oncology Program

Jason M. Samii

Fellow, R25T Molecular Imaging: Training for Oncology Program

Daniel Thorek

Research Fellow, R25T Molecular Imaging: Training for Oncology Program

Marius Erik Mayerhoefer

Attending Radiologist and is Director of PET/MRI in the Department of Radiology

Josip Ninčević

Research Fellow

Rikiya Yamashita

Research Fellow

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Hedvig Hricak discloses the following relationships and financial interests:

  • iCAD, Inc.
    Equity; Fiduciary Role / Position
  • Ion Beam Applications
    Fiduciary Role / Position

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures